摘要
The blocking of the immune checkpoint pathway with antibodies, especially targeting to programmed death-1/programmed death ligand-1 (PD-1/PD-L1) pathway, was currently a widely used treatment strategy in clinical practice. However, the shortcomings of PD -L1 antibodies were constantly exposed with the deepening of its research and their therapeutic effect was limited by the translocation and redistribution of intracellular PD -L1. Herein, we proposed to improve immune checkpoint blockade therapy by using liposomes-coated CaO2 (CaO2@Lipo) nanoparticles to inhibit the de novo biosynthesis of PD -L1. CaO2@Lipo would produce oxygen and reduce hypoxia-inducible factor-1a (HIF-1a) level, which then downregulated the expression of PD-L1. Our in vitro and in vivo results have confirmed CaO2@Lipo promoted the degradation of HIF-la and then downregulated the expression of PD -L1 in cancer cells for avoiding immune escape. Furthermore, to mimicking the clinical protocol of anti -PD -L1 antibodies + chemo-drugs, CaO2@Lipo was combined with doxorubicin (DOX) to investigate the tumor inhibition efficiency. We found CaO2@Lipo enhanced DOX-induced immunogenic cell death (ICD) effect, which then promoted the infiltration of T cells, strengthened the blocking effect, and thus provided an effective means to overcome the traditional immune checkpoint blockade treatment.
学科与关键词
- Designing Peptide-Based Nanoinhibitors of Programmed Cell Death Ligand 1 (PD-L1) for Enhanced Chemo-immunotherapyXie, Fengjuan; Tang, Shasha; Zhang, Ye; Zhao, Yinbing; Lin, Yingying; Yao, Yining; Wang, Meiyan*; Gu, Zhengying*; Wan, Jingjing*ACS Nano, 2024, 18(2): 1690-1701.
- Combining PD-L1 inhibitors with immunogenic cell death triggered by chemo-photothermal therapy via a thermosensitive liposome system to stimulate tumor-specific immunological responseYu, Jie; He, Xidong; Wang, Zigui; Wang, Yupeng; Liu, Sha; Li, Xiaoyuan*; Huang, Yubin*Nanoscale, 2021, 13(30): 12966-12978.被引 32
- Nanobubbles containing PD-L1 Ab and miR-424 mediated PD-L1 blockade, and its expression inhibition to enable and potentiate hepatocellular carcinoma immunotherapy in miceLiu, Yun; Xie, Qian; Ma, Yao; Lin, Chen; Li, Jinlin; Hu, Bing; Liu, Chaoqi*; Zhao, Yun*International Journal of Pharmaceutics, 2022, 629: 122352.被引 3
